A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis

被引:62
作者
Wilcox, CM
Darouiche, RO
Laine, L
Moskovitz, BL
Mallegol, I
Wu, J
机构
[1] BAYLOR COLL MED, HOUSTON, TX 77030 USA
[2] VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA
[3] UNIV SO CALIF, SCH MED, LOS ANGELES, CA USA
[4] JANSSEN RES FDN, TITUSVILLE, NJ USA
关键词
D O I
10.1086/514028
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This multicenter, randomized, double-blind study compared the efficacy and safety of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. One hundred twenty-six immunocompromised patients with esophageal candidiasis were treated with itraconazole oral solution or fluconazole tablets (both at 100-200 mg) once daily for 3-8 weeks, for 2 weeks beyond the resolution of symptoms, and were then followed for 4 more weeks. Severity of symptoms was assessed weekly during treatment and every 2 weeks during follow-up. Patients treated with itraconazole oral solution had a rate of clinical response (cured or improved) comparable to that of patients treated with fluconazole (94% vs, 91%). The mycologic eradication rate was 92% for itraconazole and 78% for fluconazole. Both treatments were well tolerated. Results from treatment with once-daily itraconazole oral solution was clinically comparable to those with fluconazole and is an alternative for the treatment of esophageal candidiasis in immunocompromised patients.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 35 条
[1]  
Anassi E O, 1994, Hosp Pharm, V29, P576
[2]  
ANASSI EO, 1994, HOSP PHARM, V29, P581
[3]  
ANASSI EO, 1994, HOSP PHARM, V29, P585
[4]   DNA SUBTYPES AND FLUCONAZOLE SUSCEPTIBILITIES OF CANDIDA-ALBICANS ISOLATES FROM THE ORAL CAVITIES OF PATIENTS WITH AIDS [J].
BARCHIESI, F ;
HOLLIS, RJ ;
MCGOUGH, DA ;
SCALISE, G ;
RINALDI, MG ;
PFALLER, MA .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :634-640
[5]  
BARONE JA, 1997, ENHANCED BIOAVAILABI
[6]   CANDIDA-ALBICANS GENOTYPING IN STUDIES WITH PATIENTS WITH AIDS DEVELOPING RESISTANCE TO FLUCONAZOLE [J].
BARTDELABESSE, E ;
BOIRON, P ;
CARLOTTI, A ;
DUPONT, B .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (11) :2933-2937
[7]   TREATMENT OF ORAL CANDIDOSIS WITH ITRACONAZOLE - A REVIEW [J].
BLATCHFORD, NR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (03) :565-567
[8]   FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS [J].
BOKEN, DJ ;
SWINDELLS, S ;
RINALDI, MG .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (06) :1018-1021
[9]   CORRELATION OF IN-VITRO FLUCONAZOLE RESISTANCE OF CANDIDA ISOLATES IN RELATION TO THERAPY AND SYMPTOMS OF INDIVIDUALS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
CAMERON, ML ;
SCHELL, WA ;
BRUCH, S ;
BARTLETT, JA ;
WASKIN, HA ;
PERFECT, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2449-2453
[10]   ITRACONAZOLE IN ANTIFUNGAL THERAPY [J].
CLEARY, JD ;
TAYLOR, JW ;
CHAPMAN, SW .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (04) :502-509